GreenRoc now on the EU radar after presentation on Amitsoq at the Greenland Business Mission. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.45
Bid: 6.00
Ask: 6.90
Change: 0.00 (0.00%)
Spread: 0.90 (15.00%)
Open: 6.45
High: 6.45
Low: 6.45
Prev. Close: 6.45

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

12 Nov 2020 16:34

RNS Number : 1830F
Verici Dx PLC
12 November 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

VERICI DX PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

YES

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Harwood Capital Management (Gibraltar) Limited (as investment adviser/manager) to 1.Oryx International Growth Fund Limited

and

Harwood Capital LLP (as investment adviser/manager) to 2. North Atlantic Smaller Companies Investment Trust PLC and 3 Harwood Capital LLP

 

City and country of registered office (if applicable)

1. Guernsey

2 & 3 London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

1. Oryx International Growth Fund Limited

2. North Atlantic Smaller Companies Investment Trust PLC

3. Harwood Capital LLP

 

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

3 November 2020

6. Date on which issuer notified (DD/MM/YYYY):

9 November 2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

1. 3.88%

2. 11.64%

3. 5.83%

 

1. 3.88%

2. 11.66%

 3. 5.83%

141,747,816

Position of previous notification (if

applicable)

 

 

 

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BM3HZD43

1.

2.

3.

 

5,500,000

16,500,000

8,258,572

 

3.88%

11.64%

5.83%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

30,258,572

21.35%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

3.88

0

3.88

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

Oryx International Growth Fund Ltd

 

 

 

 

 

 

 

Christopher Harwood Bernard Mills

11.64

0

11.64

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

North Atlantic Smaller Companies Investment

 

 

 

 

 

 

 

 

 

 

 

Christopher Harwood Bernard Mills

5.83

0

5.83

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

London

Date of completion

9 November 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFFRLSLFLII
Date   Source Headline
31st Jul 20247:00 amRNSLaunch of PTRA Assay using Verici Dx's technology
15th Jul 20247:00 amRNSHalf-year Report
11th Jul 20242:00 pmRNSNotice of Results and Business Update
1st Jul 20247:00 amRNSSignificant milestone re Thermo Fisher agreement
25th Jun 20241:27 pmRNSResult of AGM
18th Jun 20247:00 amRNSTransfer of urine samples to Thermo Fisher
31st May 20241:57 pmRNSNotice of AGM and posting of Annual Report
31st May 202410:00 amRNSLaunch of patient-focused educational tool
30th May 20247:00 amRNS2023 Annual Results
24th May 20247:00 amRNSNew data to be presented at ATC
27th Feb 20244:08 pmRNSHolding(s) in Company
22nd Feb 20247:00 amRNSHolding(s) in Company
21st Feb 20244:53 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSHolding(s) in Company
19th Feb 202412:35 pmRNSResult of General Meeting
14th Feb 20247:00 amRNSResult of Retail Offer
31st Jan 20247:00 amRNSVerici Dx announces new research initiative
26th Jan 202412:32 pmRNSPublication of Circular
25th Jan 202411:00 amRNSLaunch of Retail Offer
24th Jan 20246:11 pmRNSResult of Placing
24th Jan 202410:39 amRNSClose of Accelerated Bookbuild
24th Jan 20247:00 amRNSProposed Fundraising
8th Jan 20247:00 amRNSCAP accreditation
8th Jan 20247:00 amRNSMedicare National Payment Rate Confirmation
11th Dec 20237:00 amRNSTutiviaâ„¢ validation study published in Journal
29th Nov 20237:00 amRNSISO 27001 Information Security Certification
20th Nov 20237:00 amRNSInvestor Presentation
15th Nov 20237:00 amRNSCommercialisation agreement with Thermo Fisher
2nd Nov 20237:00 amRNSClaravaâ„¢ poster to be presented at ASN Kidney Week
29th Sep 20237:00 amRNSHalf-year Report
20th Jul 20237:00 amRNSCLIA Certificate of Compliance update
6th Jul 20237:00 amRNSInvestor Presentation
3rd Jul 20237:00 amRNSSuccessful clinical validation of Clarava™
29th Jun 20234:57 pmRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
5th Jun 20237:01 amRNS2022 Annual Results
5th Jun 20237:00 amRNSProposed US pricing for Tutivia™
31st May 20237:00 amRNSNotice of Results
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
24th Apr 20237:00 amRNSFinal results timing
28th Mar 202311:05 amRNSSecond Price Monitoring Extn
28th Mar 202311:00 amRNSPrice Monitoring Extension
28th Mar 20239:05 amRNSSecond Price Monitoring Extn
28th Mar 20239:00 amRNSPrice Monitoring Extension
27th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 20237:00 amRNSOperational Update
21st Mar 20234:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.